BPC-157

What Is BPC-157?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, CAS 137525-51-0) derived from a partial sequence of a gastric-juice protective protein. In preclinical models, it is studied for VEGFR2 angiogenic signalling, nitric oxide pathway modulation, and gastrointestinal mucosal cytoprotection. Evidence comes predominantly from one research group, so findings remain limited and unreplicated across independent centres. BPC-157 is supplied by RCD Bio strictly for in vitro and laboratory research use.

Disclaimer: BPC-157 is a research compound not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use. It is not intended to diagnose, treat, cure, or prevent any disease. This product is strictly for laboratory research purposes only.

BPC-157 Research Background

BPC-157 (Body Protection Compound-157), also designated Bepecin and PL 14736, was first characterised in the laboratory of Professor Predrag Sikiric at the University of Zagreb, Croatia, during systematic screening of gastric proteins for cytoprotective properties. Its defining structural feature is a triple proline cluster (Pro-Pro-Pro at positions 3–5) — a rigid, kinked backbone segment that shields the peptide from gastric proteases and gives it unusual stability in acidic conditions. A 2025 systematic review found that more than 80% of published BPC-157 records originate from this single research group, a concentration researchers should weigh when interpreting the literature. Researchers frequently search for terms such as "BPC-157 mechanism of action," "BPC-157 half-life," and "BPC-157 VEGFR2" — all of which map to preclinical observations rather than clinical outcomes.

How Does BPC-157 Work? Mechanism of Action

In preclinical models, BPC-157 is associated with several intersecting signalling pathways. All findings originate predominantly from one research group, and independent replication is limited.

VEGF/VEGFR2 Signalling Pathway

In rodent wound preparations and isolated endothelial cultures, BPC-157 has been associated with up-regulation and internalisation of vascular endothelial growth factor receptor 2 (VEGFR2), activating the downstream VEGFR2–Akt–eNOS cascade — picture receptor clustering, endocytic uptake, and phosphorylation relayed inward to endothelial nitric oxide synthase. This VEGFR2-linked signalling is proposed as a basis for the increased vessel density observed in preclinical angiogenesis assays (Hsieh et al., 2016 — reference 1).

Nitric Oxide Synthase Pathway Modulation

BPC-157 has been investigated for bidirectional modulation of the nitric oxide (NO) pathway in rodent preparations, reported to attenuate NO overproduction under inflammatory conditions while preserving NO availability in ischaemic tissue preparations — a dual profile attributed to context-dependent NOS isoform interaction.

Growth Hormone Receptor (GHR) Pathway

In isolated tendon fibroblast preparations, BPC-157 exposure has been reported to increase growth hormone receptor (GHR) mRNA and protein expression, with subsequent JAK2 signalling activation, proposed as a complementary route alongside VEGFR2 signalling in preclinical tissue-repair models (Chang et al., 2014 — reference 2).

FAK-Paxillin Signalling and Cell Migration

In fibroblast cultures, BPC-157 has been associated with phosphorylation of focal adhesion kinase (FAK) and paxillin — components of the focal adhesion complex that organise the cytoskeleton and drive directional cell migration, proposed as a mechanism for fibroblast movement into wound beds in model systems.

Key Research Areas

How Does BPC-157 Compare to Other Research Peptides?

Researchers frequently study BPC-157 alongside other angiogenic and tissue-repair peptides to contrast pathway activation profiles. This comparison is for research-context purposes only and does not imply interchangeable use, efficacy, or safety in any organism.

Purity & Quality Standards

BPC-157 offered by RCD Bio is manufactured to ≥99% purity, verified by high-performance liquid chromatography (HPLC) and mass spectrometry (MS). Each batch is accompanied by a Certificate of Analysis (CoA) available on request. This product is strictly intended for in vitro and preclinical research applications.

BPC-157 for Research — Available at RCD Bio

RCD Bio supplies BPC-157 as a lyophilised powder in 5mg and 10mg vials, each independently third-party tested and CoA-verified. Researchers who require alternative delivery formats for a laboratory protocol can also review RCD Bio's BPC-157 + TB-500 nasal spray blend listings, supplied under the same research-only, batch-traceable standard. Researchers looking to buy BPC-157 for laboratory use can order directly from RCD Bio with free U.S. shipping on qualifying orders, fast dispatch, and a Certificate of Analysis provided for every batch.

Storage & Handling Guidelines

• Store lyophilised BPC-157 at −20°C in a sealed container, protected from light and moisture.

• Once reconstituted, store at 4°C and use within 48–72 hours; avoid repeated freeze-thaw cycles.

• BPC-157 is freely soluble in water, PBS, or 0.1% acetic acid for laboratory preparation.

What Are the Risks and Limitations of BPC-157 Research?

This section is mandatory reading before working with BPC-157 in any laboratory setting.

• Handling Precautions: BPC-157 should be handled by trained laboratory personnel only, in a controlled research environment. Use nitrile gloves, a laboratory coat, and eye protection at minimum. Handle lyophilised powder in a laminar flow cabinet and avoid aerosol generation during reconstitution.

• Exposure Risks: BPC-157 is a synthetic pentadecapeptide research compound thought to interact with VEGFR2, nitric oxide synthase, and growth hormone receptor pathways in preclinical models. Because these targets are expressed in many tissues, accidental systemic exposure may produce pharmacological effects. No human safety data exist for this compound.

• Storage Risks: Improper storage (elevated temperature, light exposure, repeated freeze-thaw) may degrade peptide integrity and compromise experimental results.

• Toxicity and Data Limitations: No chronic toxicity data exist for BPC-157. Reported low-toxicity observations derive from short-duration rodent studies within a single research programme, and evidence remains limited and unreplicated across independent laboratories.

What to Look for in a Supplier When Buying Research-Grade BPC-157?

Check that every batch is independently third-party tested for purity and identity, and that a Certificate of Analysis (COA) is available for each lot. You can consider verified suppliers such as RCD Bio, where all compounds are sold strictly for preclinical and in-vitro research use.

Where to Source BPC-157 Peptide for Laboratory Research

Researchers can source third-party-tested BPC-157 peptide directly from RCD Bio, supplied strictly for laboratory and in-vitro research use. Each batch is independently verified for purity via HPLC and mass spectrometry, with a Certificate of Analysis (CoA) available for every lot. When sourcing BPC-157 for a research protocol, check that the supplier provides batch-specific CoA documentation, discloses independent third-party testing, and positions the compound explicitly for preclinical and laboratory research — not for human or veterinary use. RCD Bio supplies BPC-157 as a lyophilised powder in 5mg and 10mg vials, along with related research formats such as its BPC-157 + TB-500 nasal spray blend, all under the same batch-traceable, research-only standard.

Note: All RCD Bio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.

Disclosure: This content is for informational purposes only and does not constitute an endorsement of any product for human use.

Frequently Asked Questions About BPC-157

Q: What is BPC-157 investigated for in research?

BPC-157 is a synthetic pentadecapeptide (GEPPPGKPADDAGLV) studied in preclinical models for VEGFR2 angiogenic signalling, nitric oxide pathway modulation, growth hormone receptor expression, and gastrointestinal mucosal cytoprotection. Most published research originates from one group, and it is intended strictly for laboratory research.

Q: What is the mechanism of action of BPC-157?

In preclinical models, BPC-157 is associated with VEGFR2 internalisation and Akt-eNOS activation in endothelial cells, plus growth hormone receptor up-regulation in fibroblasts. These mechanisms are proposed, not confirmed in humans, and evidence remains limited to animal and cell-culture systems.

Q: What is the half-life of BPC-157 in preclinical models?

The elimination half-life in rat IV and IM administration is roughly 7.9–30 minutes based on preclinical pharmacokinetic data. Human pharmacokinetic data are not established.

Q: Is BPC-157 legal to purchase for research purposes?

BPC-157 is not FDA-approved for human or veterinary use and is sold strictly as a research chemical for qualified laboratory and research entities. It is prohibited under WADA S0 (Non-Approved Substances) for competitive athletes. Buyers are responsible for confirming compliance with applicable state and federal research-chemical regulations.

Q: Is BPC-157 banned by WADA?

Yes. BPC-157 is listed under Section S0 of the WADA Prohibited List as a non-approved substance, meaning it is prohibited in competitive sport at all times regardless of its research-only regulatory status.

Q: How does BPC-157 compare with TB-500 in research settings?

BPC-157 and TB-500 are both studied in tissue-repair and angiogenesis research but differ structurally and mechanistically — BPC-157 is a 15-amino-acid gastric-derived peptide linked to VEGFR2/NOS signalling, while TB-500 is a fragment of Thymosin Beta-4 studied for actin-binding and cell-migration activity. Comparative data remain preclinical, and no cross-compound efficacy conclusions can be drawn.

Q: Where can researchers buy BPC-157 for laboratory use?

Researchers can buy BPC-157 as a third-party-tested, CoA-verified lyophilised powder directly from RCD Bio in 5mg and 10mg vials, with sublingual and nasal-spray blend formats also available for laboratory protocols requiring alternative delivery formats.

Final Thoughts

BPC-157 is a synthetic gastric pentadecapeptide studied in preclinical models as a research tool for VEGFR2 angiogenic signalling, nitric oxide pathway modulation, and growth hormone receptor expression. The evidence base is concentrated in one research group and remains limited, unreplicated across independent centres, and confined to rodent and cell-culture systems. No human safety or efficacy data have been established, and BPC-157 is not approved by the FDA for human or veterinary use. Researchers should treat all reported observations as preliminary and design protocols accordingly.

References

1. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2016;95(3):323–333. https://pubmed.ncbi.nlm.nih.gov/27847966/

2. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077. https://pubmed.ncbi.nlm.nih.gov/25415472/

ATTENTION: This product is intended for LABORATORY AND RESEARCH PURPOSES ONLY. It is NOT for human or veterinary use, and NOT for human or animal consumption. Not a drug, food, or dietary supplement.